Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560



EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.

A non-opioid analgesic should be considered in populations where the use of opioids is most problematic, including:

The safety of EXPAREL has been evaluated in 21 clinical trials which include over 1300 subjects in the safety database. EXPAREL administered locally into the surgical site was evaluated in 10 randomized, double-blind clinical studies involving 823 patients undergoing various surgical procedures. Patients were administered a dose ranging from 66 mg to 532 mg of EXPAREL.2

EXPAREL is indicated for administration into the surgical site to produce postsurgical analgesia.2

Important Safety Information

Warnings and Precautions Specific to EXPAREL

Warnings and Precautions for Bupivacaine-Containing Products

For more information regarding EXPAREL, please visit the Pacira press release archives or

To report an adverse event, e-mail, dial 1-855-RX-EXPAREL (1-855-793-9727), or fax 1-858-408-3588 or 1-973-201-0649.

For medical inquiries related to EXPAREL, contact Medical Information at or 1-855-RX-EXPAREL (1-855-793-9727).

*Clinical experience with EXPAREL has not identified differences in efficacy or safety between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

1. Adamson RT, Lew I, et al. Clinical and economic implications of postsurgical use of opioid therapy. Hosp Pharm. 2011;46(6 Suppl 1):1 -8.
2. Gorfine SR, Onel E, et al. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Diseases of the Colon & Rectum. 2011;54(12):1552-1559
3. Adamson, et al. Hosp Pharm. 2011;46(6 Suppl 1):1-3.